Lundbeck Q1 2023 Financial Results and Business Update

Lundbeck's Q1 2023 earnings presentation reporting strong revenue growth of 19% at constant exchange rates and robust EBITDA expansion. The company highlights progress on its pipeline including FDA AdCom approval for brexpiprazole as an agitation treatment and positive Phase II results for its anti-PACAP program. Strategic brands delivered double-digit growth across all regions.